Top

Published in:

01-05-2016 | Original Article

Downregulation of betaine homocysteine methyltransferase (BHMT) in hepatocellular carcinoma associates with poor prognosis

Authors: Bin Jin, Zhiwei Gong, Nongguo Yang, Zhaoquan Huang, Sien Zeng, Hui Chen, Sanyuan Hu, Guangdong Pan

Published in: Tumor Biology | Issue 5/2016

Abstract

Betaine homocysteine methyltransferase (BHMT) catalyzes the synthesis of methionine using betaine and homocysteine (Hcy), which is restricted to the liver and kidney. Impaired BHMT pathway has been associated with hepatocellular carcinogenesis in Bhmt−/− mice model, and decreased BHMT was observed in a small sample of human hepatocellular carcinoma (HCC) patients. However, the prognostic significance of BHMT in HCC has not been elucidated. This study aimed to examine the expression of BHMT in HCC and investigate the relationship between its expression and prognosis of HCC patients. BHMT expression was analyzed in 68 paired HCC samples (HCC tissues vs matched adjacent non-cancerous liver tissues), 115 paraffin-embedded HCC sections (primary cohort), and 65 paraffin-embedded HCC sections (validation cohort) using immunohistochemistry (IHC). The results of IHC analysis showed that BHMT was decreased in tumorous tissues in 85.2 % (58/68) of cases compared to the corresponding adjacent non-tumorous liver tissues. Further correlation analyses indicated that the decreased BHMT expression was closely correlated with serum α-fetoprotein (AFP) (p = 0.011), tumor size (p = 0.039), and vascular invasion (p = 0.017). Moreover, HCC patients with low BHMT expression had shorter overall survival (OS) and time to recurrence (TTR) than those with high BHMT expression in both primary cohort (p < 0.0001) and validation cohort (p < 0.05) assessed by the Kaplan–Meier method. In addition, multivariate analysis showed that BHMT was an independent prognostic factor for OS and TTR in the two cohorts (all p < 0.005). Collectively, our study demonstrated that BHMT could be served as a potential prognostic marker for HCC patients.

Available only for authorised users

Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed

Sasaki Y, Yamada T, Tanaka H, et al. Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B-or hepatitis C-related hepatocellular carcinoma. Ann Surg. 2006;244:771–80.CrossRefPubMedPubMedCentral

Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63:844–55.CrossRefPubMedPubMedCentral

Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol. 2005;23:2892–9.CrossRefPubMed

Ueno M, Uchiyama K, Ozawa S, et al. Adjuvant chemolipiodolization reduces early recurrence derived from intrahepatic metastasis of hepatocellular carcinoma after hepatectomy. Ann Surg Oncol. 2011;18:3624–31.CrossRefPubMed

Hiwatashi K, Ueno S, Sakoda M, et al. Strong Smad4 expression correlates with poor prognosis after surgery in patients with hepatocellular carcinoma. Ann Surg Oncol. 2009;16:3176–82.CrossRefPubMed

Hu BS, Zhao G, Yu HF, et al. High expression of AP-4 predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy. Tumour Biol. 2013;34:271–6.CrossRefPubMed

Lu HF, Yuan WP, Li M, et al. Properly assessing CD133 as a risk factor for poor prognosis in patients with hepatocellular carcinoma after resection. Tumour Biol. 2015;36:4937–8.CrossRefPubMed

Jin H, Zhang Y, You H, et al. Prognostic significance of kynurenine 3-monooxygenase and effects on proliferation, migration, and invasion of human hepatocellular carcinoma. Sci Rep. 2015;5:10466.CrossRefPubMedPubMedCentral

10.

Millian NS, Garrow TA. Human betaine-homocysteine methyltransferase is a zinc metalloenzyme. Arch Biochem Biophys. 1998;356:93–8.CrossRefPubMed

11.

Craig SAS. Betaine in human nutrition. Am J Clin Nutr. 2004;80:539–49.PubMed

12.

Garcia-Perez A, Burg MB. Renal medullary organic osmolytes. Physiol Rev. 1991;71:1081–115.PubMed

13.

Pajares MA, Perez-Sala D. Betaine homocysteine S-methyltransferase: just a regulator of homocysteine metabolism? Cell Mol Life Sci. 2006;63:2792–803.CrossRefPubMed

14.

Delgado-Reyes CV, Wallig MA, Garrow TA. Immunohistochemical detection of betaine-homocysteine S-methyltransferase in human, pig, and rat liver and kidney. Arch Biochem Biophys. 2001;393:184–6.CrossRefPubMed

15.

Sun J, Shannon M, Ando Y, et al. Serum metabolomic profiles from patients with acute kidney injury: a pilot study. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;893:107–13.CrossRefPubMed

16.

Shinohara M, Ji C, Kaplowitz N. Differences in betaine-homocysteine methyltransferase expression, endoplasmic reticulum stress response, and liver injury between alcohol-fed mice and rats. Hepatology. 2010;51:796–805.CrossRefPubMedPubMedCentral

17.

Zhang B, Denomme MM, White CR, et al. Both the folate cycle and betaine-homocysteine methyltransferase contribute methyl groups for DNA methylation in mouse blastocysts. FASEB J. 2015;29:1069–79.CrossRefPubMed

18.

Pellanda H, Namour F, Fofou-Caillierez M, et al. A splicing variant leads to complete loss of function of betaine-homocysteine methyltransferase (BHMT) gene in hepatocellular carcinoma. Int J Biochem Cell Biol. 2012;44:385–92.CrossRefPubMed

19.

Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844–7.CrossRefPubMed

20.

Jin GZ, Li Y, Cong WM, Yu H, Dong H, Shu H, et al. iTRAQ-2DLC-ESI-MS/MS based identification of a new set of immunohistochemical biomarkers for classification of dysplastic nodules and small hepatocellular carcinoma. J Proteome Res. 2011;10(8):3418–28.CrossRefPubMed

21.

Camp RL, Dolled-Filhart M, Rimm DL. X-tile a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252–9.CrossRefPubMed

22.

Zhu AX. Systemic treatment of hepatocellular carcinoma: dawn of a new era? Ann Surg Oncol. 2010;17:1247–56.CrossRefPubMed

23.

Avila MA, Berasain C, Torres L, et al. Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J Hepatol. 2000;33:907–14.CrossRefPubMed

24.

Frau M, Simile MM, Tomasi ML, et al. An expression signature of phenotypic resistance to hepatocellular carcinoma identified by cross-species gene expression analysis. Cell Oncol (Dordr). 2012;35:163–73.CrossRef

25.

da Silva LM, Galbiatti AL, Ruiz MT, et al. MTHFD1 G1958A, BHMT G742A, TC2 C776G and TC2 A67G polymorphisms and head and neck squamous cell carcinoma risk. Mol Biol Rep. 2012;39:887–93.CrossRefPubMed

26.

Peng JP, Zhang J, Huang HW, et al. L-arginine-glycine amidinotransferase, betaine-homocysteine S-methyltransferase, and neuropolypeptide H3 are diminished in renal clear cell carcinoma of humans. Saudi Med J. 2011;32:467–73.PubMed

27.

Mostowska A, Myka M, Lianeri M, et al. Folate and choline metabolism gene variants and development of uterine cervical carcinoma. Clin Biochem. 2011;44:596–600.CrossRefPubMed

28.

Teng YW, Mehedint MG, Garrow TA, et al. Deletion of betaine-homocysteine S-methyltransferase in mice perturbs choline and 1-carbon metabolism, resulting in fatty liver and hepatocellular carcinomas. J Biol Chem. 2011;286:36258–67.CrossRefPubMedPubMedCentral

29.

Oka H, Tamori A, Kuroki T, et al. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology. 1994;19:61–6.CrossRefPubMed

30.

Iida H, Honda M, Kawai HF, et al. Ephrin-A1 expression contributes to the malignant characteristics of {alpha}-fetoprotein producing hepatocellular carcinoma. Gut. 2005;54(6):843–51.CrossRefPubMedPubMedCentral

31.

Trevisani F, Magini G, Santi V, et al. Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. Am J Gastroenterol. 2007;102:1022–31.CrossRefPubMed

32.

Huo TI, Hsu CY, Huang YH, et al. Prognostic prediction across a gradient of total tumor volume in patients with hepatocellular carcinoma undergoing locoregional therapy. BMC Gastroenterol. 2010;10:146.CrossRefPubMedPubMedCentral

33.

Sumie S, Nakashima O, Okuda K, et al. The significance of classifying microvascular invasion in patients with hepatocellular carcinoma. Ann Surg Oncol. 2014;21(3):1002–9.CrossRefPubMed

34.

Cucchetti A, Piscaglia F, Grigioni AD, et al. Preoperative prediction of hepatocellular carcinoma tumour grade and micro-vascular invasion by means of artificial neural network: a pilot study. J Hepatol. 2010;52(6):880–8.CrossRefPubMed

Title: Downregulation of betaine homocysteine methyltransferase (BHMT) in hepatocellular carcinoma associates with poor prognosis
Authors: Bin Jin
Zhiwei Gong
Nongguo Yang
Zhaoquan Huang
Sien Zeng
Hui Chen
Sanyuan Hu
Guangdong Pan
Publication date: 01-05-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 5/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-4443-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2016

miR-874 suppresses the proliferation and metastasis of osteosarcoma by targeting E2F3

Fisetin and hesperetin induced apoptosis and cell cycle arrest in chronic myeloid leukemia cells accompanied by modulation of cellular signaling

Circulating long noncoding RNA GAS5 as a potential biomarker in breast cancer for assessing the surgical effects

The small conductance calcium-activated potassium channel 3 (SK3) is a molecular target for Edelfosine to reduce the invasive potential of urothelial carcinoma cells

Cancer stem cells, metabolism, and therapeutic significance

MTUS1 and its targeting miRNAs in colorectal carcinoma: significant associations

Keynote webinar | Spotlight on antibody–drug conjugates in cancer